Navigation Links
Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
Date:9/5/2007

omized trial of pixantrone versus doxorubicin is also a very important recognition of the potential toxicity benefit of this novel agent."

The Company recently announced results of an interim analysis of the RAPID trial which showed that patients who received pixantrone had a reduction in severe (grade 3/4) side effects when compared to patients treated with standard doxorubicin-based therapy. Despite pixantrone patients receiving more treatment cycles, a three-fold reduction in the incidence of severe heart damage (LVEF decline >15 percent) was seen as well as clinically significant reductions in severe infections and febrile neutropenia.

The Data Safety Monitoring Committee, which met recently, recommended that the EXTEND study continue. The trial is expected to be completed by the end of 2007 with a full analysis during the first half of 2008. Since pixantrone has fast track status for relapsed, aggressive NHL, the drug could receive marketing approval in 2009.

About EXTEND (PIX301)

The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who have received two or more prior therapies and who are sensitive to treatment with anthracyclines. The trial is being conducted at 130 sites in 17 countries. Patients are randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician. The trial is designed to examine the complete response (CR) or unconfirmed complete response (uCR) rate, time to tumor progression, and overall survival. The study was powered based on a CR rate assumption of less than 5 percent for the control arm and a 10 percent improvement in CR rate for the pixantrone arm. The study initially anticipated the requirement of 320 patients to meet the statistical assumptions of the trial. The study is being conducted under a Special Protocol Assessment from the U.S.
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Extended data analysis using DeCyder EDA
2. Detection of N-in-1 Experiments: Extending the Range of N Using the API 3000 LC/MS/MS System
3. Techware to extend broadband wireless network to Butler
4. UW gets $5M to extend entrepreneurship
5. Creativity, innovation extend to municipalities
6. NimbleGen extends research market reach
7. TomoTherapy extends reach to Germany
8. Third Wave says patent extends IP reach
9. `Single-sales factor extends tax treatment to tech, service firms
10. Alumni Association extends database help to university
11. UW-Madison working to extend wireless access to entire campus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Product and process impurities ... abundance and are often “lost in the noise,” ... Join presenters Dr. Rowel Tobias, Senior Scientist, Protein ... Head of Quality at Nanotherapeutics, Inc., to lear ... speed detection and quantitation while achieving the required ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
(Date:7/10/2014)... 10, 2014 On July 9 ... , presented Russia,s first national ... The Company is developing a unique project called ... develops a number of innovative drugs based on monoclonal ... ceremony took place at the International Exhibition "Innoprom 2014" ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2
... expands Dermagraft presence within government channels, ... 7 Advanced,BioHealing, Inc. (ABH) and Regenesis ... the promotion of Dermagraft(R) within the United,States ... the agreement,Regenesis will provide its specialized sales ...
... this Mother,s Day, STAMFORD, Conn., May 7 Every ... breast cancer(1). In New York City alone,more than 5,000 women ... the disease(2). While annual mammograms are recommended for,woman over the ... screening age do,not recognize how critical breast cancer screening is ...
... Inc., Elliott Sigal, M.D., Ph.D, from Bristol-Myers Squibb Company, Federico ... FDA, ... IBC Life Sciences announced,the keynote line up for the ... to take place August 4-7, 2008 in,Boston, MA. The keynote ...
Cached Biology Technology:Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R) 2Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R) 3Fujifilm and the National Breast Cancer Foundation Provide Free Mammograms as Part of Images of Health Campaign 2Fujifilm and the National Breast Cancer Foundation Provide Free Mammograms as Part of Images of Health Campaign 3Fujifilm and the National Breast Cancer Foundation Provide Free Mammograms as Part of Images of Health Campaign 4Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBC's 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress 2
(Date:7/11/2014)... Tenn., July 11, 2014--Researchers at the Department of ... R&D 100 awards, presented by R&D Magazine in ... , "These awards recognize the tremendous value of ... Moniz. "Research and development at the National Labs ... challenges and pursue the scientific and technological innovations ...
(Date:7/11/2014)... a new professorship in tissue engineering to promote ... Engineering and the Marine Biological Laboratory, supported by ... Eugene Bell Foundation., The Eugene Bell Professorship in ... Molecular Engineering. That endowed chair holder also will ... Bell Center for Regenerative Biology and Tissue Engineering, ...
(Date:7/11/2014)... 10, 2014---A team of researchers from The Chinese University ... a gene of wild soybean linked to salt tolerance, ... in saline soil. This study published online in ... novel genomic information for crop improvement. , Soybean is ... and human selection, cultivated soybeans have less genetic diversities ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... UK, July 20, 2011 - Recent clinical research ... [18F]Flutemetamol showed highly consistent image interpretation1 and showed ... ([C-11]PiB)) investigational imaging agent3. Flutemetamol is a GE ... currently in phase III development being studied for ...
... an arterial wall effectively protects the artery from developing ... published July 19 in the journal Molecular Therapy ... atherosclerosis, fatty lesions called plaques form on the inner ... restricting blood flow and causing chest pains and other ...
... A new Baylor University study has found that some bird ... some cases positively influenced, by widespread fire through their habitat. ... some bird species because of the habitat that is formed ... The study found that three specific bird species in ...
Cached Biology News:GE Healthcare studies report results of [18F]Flutemetamol research 2Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies 2Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies 3Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies 4Study finds some desert birds less affected by wildfires and climate change 2
Alkali soluble casein is the recommended blot blocking reagent for use with the HisTag Monoclonal Antibody (Novagen) on Western blots....
... This reagent has been developed for ... the reduction of nonspecific background staining ... methods describe blocking peroxidase with hydrogen ... peroxide in combination with additional novel ...
Anti-Human Factor XI Purified (Polyclonal) (sheep IgG)...
Formulation: 10mM PBS/500 mM NaCl, 0.09% NaN3, pH 7.2...
Biology Products: